Related Experiment Videos
[Laboratory and clinical studies on cefpirome in pediatrics]
1Department of Pediatrics, Nagasaki Central National Hospital.
Insights
Cefpirome (CPR) is a new cephem antibiotic showing high efficacy and safety in children. This study evaluated its absorption, elimination, and clinical effectiveness in pediatric patients with various infections.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Research
Background:
- Cephem antibiotics are crucial in treating bacterial infections.
- New antibiotics are needed to combat evolving resistance patterns.
- Cefpirome (CPR) is a novel cephem antibiotic developed for therapeutic use.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of cefpirome (CPR) in pediatric patients.
- To assess the clinical efficacy and safety of CPR in treating various pediatric infections.
- To determine optimal administration routes and dosages for CPR in children.
Main Methods:
- Pharmacokinetic analysis of CPR in 7 children via intravenous bolus injection and drip infusion.
- Bioassay using Bacillus subtilis ATCC 6633 to determine serum drug concentrations (Cmax).
- Clinical evaluation of CPR in 20 pediatric patients with diverse bacterial infections.
Main Results:
- CPR demonstrated varying serum levels and elimination half-lives depending on administration method.
- High clinical efficacy rate of 94.7% was observed across treated pediatric infections.
- No adverse reactions were reported in any patients; minimal laboratory abnormalities noted.
Conclusions:
- Cefpirome (CPR) exhibits favorable pharmacokinetic properties and a high efficacy rate in pediatric patients.
- CPR is considered a safe and effective antibiotic for treating a range of infectious diseases in children.
- Further research may explore broader applications and long-term safety of CPR in pediatric populations.
Abstract:
Laboratory and clinical studies on cefpirome (CPR, HR 810), a newly developed cephem antibiotic, were performed. The results obtained are summarized as follows: 1. Absorption and elimination of the drug were examined in a total of 7 children including 3 cases of administered with 20 mg/kg intravenous bolus injection (i.v.), 2 cases with 20 mg/kg drip infusion (d.i.v.) for 60 minutes and 2 cases with 40 mg/kg (d.i.v.) for 60 minutes. Maximum serum levels were attained immediately after i.v. or d.i.v. Cmax's were 233 +/- 7.6, 88.5 +/- 14.5, and 116 +/- 15 micrograms/ml, respectively for the above 3 modes of administration. These values were determined using a bioassay method with Bacillus subtilis ATCC 6633. T 1/2 (beta)'s were 1.18 +/- 0.17, 1.61 +/- 0.28 and 2.68 +/- 0.83 hours, respectively. Cumulative urinary recovery rates were 40.2-69.8% in a period of 0-6 hours after admissions. 2. Clinical efficacies were evaluated in a total of 20 patients with ages ranging from 9 months to 11 years. The treated cases were 6 cases of acute pneumonia, 4 cases of acute bronchitis, 4 cases of acute purulent tonsillitis, 2 cases of acute urinary tract infections, 2 cases of cellulitis, 1 case of purulent lympadenitis and 1 case of acute otitis media. The clinical efficacy rate was 94.7%. Adverse reactions occurred in no patients. Abnormal changes in laboratory test values involved only 1 case with elevated GOT and GPT. CPR was considered to be a safe and useful drug in treating various infectious diseases in children.